Skip to content
Dermavant Sciences, an Organon company logo — A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, an Organon company

A Passion for Science and a Commitment to Dermatology

Founded 2016 United States Long Beach, United States 161 employees Private Equity Total: $160.00M Biotechnology, Health Care

General Information

Company Name Dermavant Sciences, an Organon company
Founded Year 2016
Location United States Long Beach, United States
Employees 161
Industries Biotechnology, Health Care
Funding Stage Private Equity
Business Model B2B, B2D
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Dermavant Sciences, an Organon company. To contact Dermavant Sciences, an Organon company, visit dermavant.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Dermavant Sciences, an Organon company compare?

A PDF of Dermavant Sciences, an Organon company and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Dermavant Sciences, an Organon company soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Dermavant Sciences, an Organon company

Dermavant Sciences, an Organon company, operates within the Biotechnology and Health Care industries. Founded in 2016 and headquartered in the United States, Dermavant has carved a niche in the specialty biopharmaceutical sector by focusing on cutting-edge therapies for dermatologic diseases.

The company's tagline, "A Passion for Science and a Commitment to Dermatology," encapsulates its mission. Dermavant's strategy involves acquiring promising compounds to address unmet therapeutic needs, rapidly building a robust dermatology R&D pipeline. Their commitment lies in developing and commercializing novel first-in-class or best-in-class therapies aimed at enhancing patients' lives.

In its latest financial move, Dermavant raised $160.00M in a Private Equity Round on 07 June 2021, backed by significant investors like Marathon Fund and Novaquest Capital Management. Dermavant represents an attractive prospect for investors seeking innovation-driven growth in dermatological biopharmaceutical solutions.

Business keywords: biopharmaceutical, dermatology, prescription therapies, dermatologic diseases, therapeutic needs, R&D pipeline, biomedical research, novel therapies, first-in-class, best-in-class, patient-focused, innovative compounds, specialty pharmaceuticals, disease treatment

Services & Products

Development and distribution of women's health medicines and devices
Provision of biosimilars
Offering established brands across multiple therapeutic areas
Healthcare solutions for specific women-related conditions

Target Customers

Women across all stages of life Healthcare professionals Healthcare systems Patients requiring cardiovascular, neurological, dermatological, respiratory, and reproductive health solutions

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round $160.00M 2
Marathon Fund, Novaquest Capital Management
07 Jun 2021

Dermavant Sciences, an Organon company Alternatives & Competitors

View All Alternatives
Dermavant Sciences, an Organon company vs
Visterra Inc.
Visterra Inc. United States

We bring better biologics to life. Biospace Best Place to Work 2024!

Series C
139 employees
Biotechnology, Health Care
Dermavant Sciences, an Organon company vs
Aceragen
Aceragen United States

Aceragen is a rare disease company striving to restore a better life for patients and families.

Private Equity
2 employees
Biotechnology, Health Care
Dermavant Sciences, an Organon company vs
Ultragenyx
Ultragenyx United States

Going Beyond Every Day

Post-IPO Equity
1535 employees
Biotechnology, Health Care

FAQ About Dermavant Sciences, an Organon company

A Passion for Science and a Commitment to Dermatology
Dermavant Sciences, an Organon company was founded in 2016.
Dermavant Sciences, an Organon company is headquartered in Long Beach, United States.
Dermavant Sciences, an Organon company operates in Biotechnology and Health Care. Its work centres on biopharmaceutical, dermatology, prescription therapies and dermatologic diseases. Its customers include Women across all stages of life, Healthcare professionals and Healthcare systems.
Dermavant Sciences, an Organon company has a B2B and B2D business model. Its revenue comes from Product Sales and Licensing.
Dermavant Sciences, an Organon company has approximately 161 employees.
Dermavant Sciences, an Organon company has completed 1 funding round, raising a total of $160.00M. The latest funding stage is Private Equity.
Dermavant Sciences, an Organon company offers: Development and distribution of women's health medicines and devices, Provision of biosimilars, Offering established brands across multiple therapeutic areas, Healthcare solutions for specific women-related conditions.
Top alternatives and competitors to Dermavant Sciences, an Organon company include Visterra Inc., Aceragen, Ultragenyx, Azura Ophthalmics Limited, AMO Pharma LTD. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Dermavant Sciences, an Organon company and Visterra Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Dermavant Sciences, an Organon company, https://bouncewatch.com/company/dermavant-sciences, updated 4 February 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout